Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform
This image was generated by AI and may not depict real events.
Lightcast, a life science tools company, has raised $27 million to accelerate the commercialization of its Envisia platform, which enables functional single-cell analysis. The company has also appointed industry veteran Brad Crutchfield as an advisor to support its early access growth and global launch.
Lightcast, a life science tools company, has raised $27 million from existing investors. The financing will support the full commercial release of its Envisia benchtop platform in 2026. The platform enables functional single-cell analysis, allowing researchers to move beyond inference and directly measure function at the level of individual cells. Lightcast has expanded its early access program, working with leading pharmaceutical and academic institutions to validate platform performance. The company has appointed Brad Crutchfield as an advisor to support its growth and launch. The Envisia platform captures rich functional data directly, powered by Lightcast's proprietary technology.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.